Monitor NMPA approval decisions for OncoScreen BCMatch and CanCatch kits, which could drive future revenue growth. The sequential recovery from Q1 is positive but insufficient to offset the YoY decline; watch for sustained in-hospital growth and stabilization of pharma R&D revenue in Q3.
Price Chart
Executive Summary
Burning Rock reported Q2 2026 revenue of RMB134.7M ($19.9M), a 9.3% YoY decline, with a net loss widening to RMB18.4M from RMB9.7M a year ago. In-hospital business grew 7.4% YoY, but central lab and pharma R&D services both declined sharply. No guidance or consensus comparison was provided, making the earnings surprise calculation unreliable; the sequential recovery from Q1 is the key narrative, but the overall financial deterioration is clear.
Key Financial Metrics
Key Facts
- Revenue declined 9.3% YoY to RMB134.7M ($19.9M)
- Net loss widened to RMB18.4M from RMB9.7M YoY
- Central lab revenue fell 10.0% YoY; pharma R&D services fell 31.8% YoY
- In-hospital business grew 7.4% YoY, partially offsetting declines
- Gross margin stable at 72.6% vs 72.8% YoY
- Cash and equivalents at RMB419.1M ($61.8M) as of June 30, 2026
- Several products entered NMPA priority review channels, but no near-term revenue impact
Financial Impact
Revenue decline of 9.3% YoY; net loss increased by 89.7% YoY to RMB18.4M
Risk Factors
- Continued revenue decline if central lab and pharma R&D segments do not stabilize
- Regulatory approval delays for NMPA priority review products
- Cash burn rate of ~RMB51.7M per six months limits runway without additional funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359378 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $11.62 $15.20 | ▼ −30.81% | ▼ −28.68% | $12.13 (−4.39%) |
Sep 10, 2026 6w ago | 6-K | $11.62 $15.20 | ▼ −30.81% | ▼ −28.68% | $12.13 (−4.39%) |
Jun 9, 2026 19w ago | Press Release | $8.18 $10.75 | ▼ −31.36% | ▼ −29.91% | $12.13 (−48.29%) |
Jun 9, 2026 19w ago | 6-K | $8.18 $10.75 | ▼ −31.36% | ▼ −29.91% | $12.13 (−48.29%) |
Apr 28, 2026 25w ago | Press Release | $16.65 $12.17 | ▼ −26.91% | ▼ −32.36% | $12.13 (−27.15%) |
Mar 12, 2026 32w ago | Press Release | $22.85 $15.85 | ▼ −30.66% | ▼ −32.63% | $12.13 (−46.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers